NeuroBo Pharmaceuticals, Inc. – NASDAQ:NRBO

NeuroBo Pharmaceuticals stock price today

$2.36
-2.64
-52.8%
Financial Health
0
1
2
3
4
5
6
7
8
9

NeuroBo Pharmaceuticals stock price monthly change

+30.21%
month

NeuroBo Pharmaceuticals stock price quarterly change

+28.54%
quarter

NeuroBo Pharmaceuticals stock price yearly change

+1087.65%
year

NeuroBo Pharmaceuticals key metrics

Market Cap
20.33M
Enterprise value
N/A
P/E
-0.04
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
0.07
PEG ratio
N/A
EPS
-3.27
Revenue
N/A
EBITDA
-23.31M
Income
-16.58M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

NeuroBo Pharmaceuticals stock price history

NeuroBo Pharmaceuticals stock forecast

NeuroBo Pharmaceuticals financial statements

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO): Profit margin
Jun 2023 0 -734K
Sep 2023 0 -3.81M
Dec 2023 4K -5.31M -132850%
Mar 2024 0 -6.71M
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO): Analyst Estimates
2025 7K -30.03M -429028.57%
2026 7K -34.44M -492047.57%
  • Analysts Price target

  • Financials & Ratios estimates

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO): Debt to assets
Jun 2023 29179000 3.98M 13.65%
Sep 2023 26425000 4.87M 18.45%
Dec 2023 22781000 6.09M 26.76%
Mar 2024 17018000 6.94M 40.79%
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO): Cash Flow
Jun 2023 -2.04M 0 -80
Sep 2023 -2.81M -37K 0
Dec 2023 -3.39M -9K 0
Mar 2024 -6.44M -5K 0

NeuroBo Pharmaceuticals alternative data

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO): Employee count
Aug 2023 2
Sep 2023 2
Oct 2023 2
Nov 2023 2
Dec 2023 2
Jan 2024 2
Feb 2024 2
Mar 2024 2
Apr 2024 2
May 2024 8
Jun 2024 8
Jul 2024 8

NeuroBo Pharmaceuticals other data

2.29% -97.71%
of NRBO is owned by hedge funds
59.05K -1.33M
shares is hold by hedge funds

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO): Insider trades (number of shares)
Period Buy Sel
Jun 2024 5089060 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
DONG-A ST CO., LTD 10 percent owner
Common Stock 5,089,060 $3.53 $17,964,382
Purchase
RENO SETH officer: Chief Commercial Officer
Common Stock 14,286 $7 $100,002
Purchase
GULLANS STEVEN R. PH.D. director
Common Stock 71,429 N/A N/A
Option
MATHIESEN JEFFREY S officer: Chief Financial Officer
Common Stock 3,207 $3.59 $11,513
Option
MATHIESEN JEFFREY S officer: Chief Financial Officer
Employee Stock Option (right to buy) 3,207 $3.59 $11,513
Option
MATHIESEN JEFFREY S officer: Chief Financial Officer
Common Stock 3,000 $3.59 $10,770
Option
MATHIESEN JEFFREY S officer: Chief Financial Officer
Employee Stock Option (right to buy) 6,000 $3.59 $21,540
Option
MATHIESEN JEFFREY S officer: Chief Financial Officer
Employee Stock Option (right to buy) 6,000 $1.8 $10,770
Option
BISGAIER CHARLES PHD director, 10 percent owner, off..
Employee Stock Option (right to buy) 4,474 N/A N/A
Option
BISGAIER CHARLES PHD director, 10 percent owner, off..
Common Stock 4,474 N/A N/A
Patent
Application
Filling date: 15 Oct 2021 Issue date: 3 Feb 2022
Application
Filling date: 8 Feb 2021 Issue date: 16 Sep 2021
Application
Filling date: 13 Nov 2020 Issue date: 6 May 2021
Grant
Filling date: 16 Mar 2020 Issue date: 16 Mar 2021
Grant
Filling date: 3 Dec 2015 Issue date: 15 Dec 2020
Application
Filling date: 16 Mar 2020 Issue date: 17 Sep 2020
Application
Filling date: 17 Oct 2019 Issue date: 13 Aug 2020
Grant
Filling date: 29 Jun 2018 Issue date: 14 Jul 2020
Grant
Filling date: 3 Dec 2015 Issue date: 17 Mar 2020
Monday, 18 November 2024
prnewswire.com
Wednesday, 13 November 2024
prnewswire.com
Thursday, 7 November 2024
prnewswire.com
Monday, 4 November 2024
prnewswire.com
Tuesday, 1 October 2024
prnewswire.com
Monday, 30 September 2024
prnewswire.com
Tuesday, 3 September 2024
prnewswire.com
Wednesday, 14 August 2024
prnewswire.com
Tuesday, 13 August 2024
prnewswire.com
Tuesday, 6 August 2024
prnewswire.com
Tuesday, 30 July 2024
prnewswire.com
Thursday, 11 July 2024
prnewswire.com
Sunday, 30 June 2024
247wallst.com
Tuesday, 25 June 2024
prnewswire.com
Monday, 24 June 2024
prnewswire.com
Saturday, 22 June 2024
prnewswire.com
Wednesday, 22 May 2024
prnewswire.com
Thursday, 9 May 2024
prnewswire.com
Tuesday, 30 April 2024
PRNewsWire
Monday, 12 February 2024
PRNewsWire
Monday, 5 February 2024
InvestorPlace
Tuesday, 2 January 2024
PRNewsWire
Friday, 1 December 2023
PRNewsWire
Tuesday, 17 October 2023
PRNewsWire
Friday, 29 September 2023
Zacks Investment Research
Thursday, 28 September 2023
Zacks Investment Research
Thursday, 29 June 2023
PennyStocks
Tuesday, 27 June 2023
PennyStocks
Tuesday, 6 June 2023
Zacks Investment Research
Wednesday, 19 April 2023
PennyStocks
  • What's the price of NeuroBo Pharmaceuticals stock today?

    One share of NeuroBo Pharmaceuticals stock can currently be purchased for approximately $2.36.

  • When is NeuroBo Pharmaceuticals's next earnings date?

    Unfortunately, NeuroBo Pharmaceuticals's (NRBO) next earnings date is currently unknown.

  • Does NeuroBo Pharmaceuticals pay dividends?

    No, NeuroBo Pharmaceuticals does not pay dividends.

  • How much money does NeuroBo Pharmaceuticals make?

    NeuroBo Pharmaceuticals has a market capitalization of 20.33M.

  • What is NeuroBo Pharmaceuticals's stock symbol?

    NeuroBo Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "NRBO".

  • What is NeuroBo Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of NeuroBo Pharmaceuticals?

    Shares of NeuroBo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does NeuroBo Pharmaceuticals have?

    As Jul 2024, NeuroBo Pharmaceuticals employs 8 workers, which is 300% more then previous quarter.

  • When NeuroBo Pharmaceuticals went public?

    NeuroBo Pharmaceuticals, Inc. is publicly traded company for more then 9 years since IPO on 5 Aug 2016.

  • What is NeuroBo Pharmaceuticals's official website?

    The official website for NeuroBo Pharmaceuticals is neurobopharma.com.

  • Where are NeuroBo Pharmaceuticals's headquarters?

    NeuroBo Pharmaceuticals is headquartered at 200 Berkeley Street, Boston, MA.

  • How can i contact NeuroBo Pharmaceuticals?

    NeuroBo Pharmaceuticals's mailing address is 200 Berkeley Street, Boston, MA and company can be reached via phone at 857 702 9600.

NeuroBo Pharmaceuticals company profile:

NeuroBo Pharmaceuticals, Inc.

neurobopharma.com
Exchange:

NASDAQ

Full time employees:

8

Industry:

Biotechnology

Sector:

Healthcare

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

200 Berkeley Street
Boston, MA 02116

CIK: 0001638287
ISIN: US64132R4048
CUSIP: 64132R107